Indivior Pharmaceuticals, Inc. (INDV) Q3 2025 10-Q Quarterly Report
Indivior Pharmaceuticals, Inc. (INDV) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 30, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Indivior Pharmaceuticals, Inc. Q3 2025 10-Q Analysis
Management Discussion & Analysis
- • No revenue or profitability details disclosed in this MD&A excerpt
- • No segment or product line performance data provided
Risk Factors
- • New regulatory risk from 2025 OBBBA law, potentially limiting patient eligibility and treatment access for OUD starting 2027-2028
- • Material update: CMS finalized Marketplace Integrity and Affordability Regulation in June 2025, changing ACA open enrollment and premium tax credit eligibility
Indivior Pharmaceuticals, Inc. Q3 2025 Quarterly FinancialsXBRL
Revenue
$313M
▲ +3.6% QoQ
Net Income
$43M
▲ +138.9% QoQ
Gross Margin
73.5%
▼ -963bp QoQ
Operating Margin
13.7%
▼ -1010bp QoQ
Net Margin
13.7%
▲ +778bp QoQ
ROE
-20.8%
Total Assets
$1.4B
EPS (Diluted)
$0.33
▲ +135.7% QoQ
Operating Cash Flow
-$39M
▼ -124.7% QoQ
Source: XBRL data from Indivior Pharmaceuticals, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Indivior Pharmaceuticals, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.